PARTNER CONTENT by DO NOT USE T ROWE PRICE
This content was paid for and produced by DO NOT USE T ROWE PRICE
Value vs. growth – who wins?
Global equities have advanced as investors have weighed the worsening coronavirus pandemic against hopes of a potential coronavirus vaccine. As sentiment rises, however, we believe it makes sense to be prudent in terms of portfolio positioning. To be clear, we are optimistic as we look out over one to two years, but we are seeing a second wave of the virus spread, and it is proving to be more extended than the first wave in many places. Vaccine developments are a clear positive, but the market’s reaction to the prospect of a post coronavirus world creates some near term uncertainty and risk.
One question on investors’ minds is that of value versus growth. Thoughts of a post coronavirus world understandably cause excitement and rotation toward all things “cheap.” However, if the economic recovery is disrupted for any prolonged period, markets may favor the Covid on beneficiaries, which tend to sit on the growth side of the style spectrum.
For us, it is not a matter of timing a style cycle. We do not think this is the time to make a call on value versus growth. Instead, we believe the key is to maintain portfolio breadth, diversification and apply risk control and active stock decision making as we work through what is going to be an uneven path of recovery and improvement. Valuations are important and we need to manage pockets of excessive optimism, along with any uncertainty that arises with respect to US policymaking.
Find out more
